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Mitochondrial Potassium Channel Opener Diazoxide
Preserves Neuronal-Vascular Function After Cerebral
Ischemia in Newborn Pigs
Ferenc Domoki, MD; James V. Perciaccante, MD; Roland Veltkamp, MD;
Ferenc Bari, PhD; David W. Busija, PhD
Background and Purpose—N-Methyl-D-aspartate (NMDA) elicits neuronally mediated cerebral arteriolar vasodilation
that is reduced by ischemia/reperfusion (I/R). This sequence has been preserved by pretreatment with the ATP-sensitive
potassium (KATP) channel opener aprikalim, although the mechanism was unclear. In the heart, mitochondrial KATP
channels (mitoKATP) are involved in the ischemic preconditioning-like effect of K1 channel openers. We determined
whether the selective mitoKATP channel opener diazoxide preserves the vascular dilation to NMDA after I/R.
Methods—Pial arteriolar diameters were determined with the use of closed cranial window/intravital microscopy in
anesthetized piglets. Vascular responses to NMDA were assessed before and 1 hour after 10 minutes of global cerebral
ischemia induced by raising intracranial pressure. Subgroups received 1 of the following pretreatments before I/R:
vehicle; 1 to 10 mmol/L diazoxide; and coapplication of 100 mmol/L 5-hydroxydecanoic acid (5-HD), a KATP antagonist
with diazoxide.
Results—NMDA-induced dose-dependent pial arteriolar dilation was not affected by diazoxide treatment only but was
severely attenuated by I/R. In contrast, diazoxide dose-dependently preserved the NMDA vascular response after I/R;
at 10 mmol/L, diazoxide arteriolar responses were unaltered by I/R. The effect of diazoxide was antagonized by
coapplication of 5-HD with diazoxide. Percent preservation of 100 mmol/L NMDA–induced vasodilation after I/R was
53619% (mean6SEM, n58) in vehicle-treated controls versus 55610%, 8565%, and 99615% in animals pretreated
with 1, 5, and 10 mmol/L diazoxide (n58, n58, and n512, respectively) and 60615% in the group treated with
5-HD1diazoxide (n55).
Conclusions—The mitoKATP channel opener diazoxide in vivo preserves neuronal function after I/R, shown by pial
arteriolar responses to NMDA, in a dose-dependent manner. Thus, activation of mitoKATP channels may play a role in
mediating the protective effect of other K1 channel openers. (Stroke. 1999;30:2713-2719.)
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Glutamate elicits cerebral arteriolar vasodilation in pigletsvia a multistep process, involving activation of neuronal
N-methyl-D-aspartate (NMDA) receptors, stimulation of nitric
oxide (NO) production by neuronal NO synthase, and actions of
NO on vascular smooth muscle cells.1–3 This sequence of events
may represent an important mechanism coupling local blood
flow to metabolism and neuronal activity.
NMDA-induced vasodilation is attenuated by hypoxia and
ischemia/reperfusion (I/R) in a dose- and time-dependent
manner.4–6 For example, 10 minutes of global ischemia
followed by reperfusion reduces NMDA-induced vasodila-
tion by '50%. However, arteriolar dilator responses to
exogenously applied NO are intact,5,6 thereby implying that
the attenuation of the vascular response to NMDA is due to
See Editorial Comment, page 2718
effects of ischemia at the level of the neurons. Furthermore,
results from other laboratories as well as our own indicate that
dysfunction of the NMDA receptor rather than of general
neuronal injury is the primary reason for attenuated arteriolar
responsiveness to NMDA.5,7 The mechanisms involved in
attenuated arteriolar dilation to NMDA are not known with
certainty but appear to involve actions of reactive oxygen
species (ROS), such as superoxide anion. Thus, pharmaco-
logical agents that prevent production of superoxide anion or
that scavenge this radical prevent attenuation of NMDA-
induced dilator responses.4,5,8
In our laboratory, NMDA-induced vasodilation has been
used as a sensitive bioassay to assess the functional integrity
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of the neuronal-vascular axis. For instance, we have shown
that activation of ATP-sensitive potassium (KATP) channels
with aprikalim for a short period immediately before com-
bined hypoxic/ischemic stress preserves pial arteriolar dila-
tion to NMDA.6 Possible mechanisms of action of KATP
activation may be via hyperpolarization of neurons through
plasmolemmal KATP channels, which may result in (1) re-
duced glutamate release, (2) smaller increases in intracellular
Ca21 levels during ischemia, or possibly (3) less ROS
production during reperfusion. However, intracellular sites of
action of K1 channel activators have not been considered
previously.
Mitochondrial KATP (mitoKATP) channels have been found
in the inner membrane of mitochondria9 and represent a
pharmacologically distinct population of KATP channels.10
There is increasing evidence about the diverse functions of
mitoKATP channels in the regulation of mitochondrial matrix
volume, ATP production, and Ca21 homeostasis in mitochon-
dria, essential factors determining the outcome of ischemic
stress on cellular function and survival.11–14 In fact, several
K1 channel openers can mimic ischemic preconditioning
(IPC) in the heart,15 and mitoKATP channels are certainly
involved in mediating these effects.16–18 However, no study
has investigated the possible beneficial role of mitoKATP
channel activation in vivo in the brain and the cerebral
circulation.
In this study our purpose was to determine whether
diazoxide, a selective mitoKATP channel opener, would pre-
serve the NMDA-induced arteriolar dilation 1 hour after 10
minutes of global cerebral ischemia. Additionally, we inves-
tigated whether 5-hydroxydecanoic acid (5-HD), a relatively




Newborn piglets of either sex (age, 1 to 7 days; body weight, 1 to 2
kg) were used. All procedures were approved by the Institutional
Animal Care and Use Committee. The animals were anesthetized
with sodium thiopental (30 to 40 mg/kg IP) followed by injection of
a-chloralose (75 mg/kg IV). Supplemental doses of a-chloralose
were given to maintain a stable level of anesthesia. The right femoral
artery and vein were catheterized to record blood pressure and to
administer drugs and fluids, respectively. The piglets were intubated
via tracheotomy and artificially ventilated with room air. The
ventilation rate ('20/min) and tidal volume ('20 mL) were adjusted
to maintain arterial blood gas values and pH in the physiological
range. Body temperature was maintained at 37°C to 38°C by a
water-circulating heating pad. Body temperature, arterial pH, and
blood gases were also in the normal ranges and did not vary
significantly among different groups. For instance, in group 5, the
values were as follows: body temperature, 37.960.2°C; pH,
7.5160.03; PCO2, 33.361.9 mm Hg; and PO2, 9764 mm Hg.
The head of the piglet was fixed in a stereotaxic frame. The scalp
was incised and removed along with the connective tissue over the
calvaria. A circular (19 mm in diameter) craniotomy was made in the
left parietal bone. The dura was cut and reflected over the skull. A
stainless steel cranial window with 3 needle ports was placed into the
craniotomy, sealed with bone wax, and cemented with cyanoacrylate
ester (Super Glue) and dental acrylic.
The closed window was filled with artificial cerebrospinal fluid
(aCSF) warmed to 37°C and equilibrated with 6% O2 and 6.5% CO2
in balance N2 to give pH57.33, PCO2546 mm Hg, and
PO2543 mm Hg. The aCSF consisted of the following (mmol/L):
NaCl 132, KCl 2.9, CaCl2 1.2, MgCl2 1.4, NaHCO3 24.6, urea 6.7,
and glucose 3.7. Diameters of pial arterioles were measured with a
microscope (Wild M36) equipped with a video camera (Panasonic)
and a video micro scaler (IV-550, For-A-Co). After surgery, the
cranial window was gently perfused with aCSF until a stable baseline
was obtained. At the end of the experiments, the animals were killed
while anesthetized with an intravenous bolus of KCl.
Cerebral Ischemia
To induce global cerebral ischemia, a 3-mm hole was made by an
electric drill with a toothless bit, and the dura was exposed. A hollow
brass bolt was inserted in the left frontal cranium rostral to the cranial
window and secured in place with cyanoacrylate ester and dental
acrylic. Cerebral ischemia was produced by infusion of aCSF to raise
intracranial pressure above arterial pressure. Ischemia was verified
by the cessation of blood flow in the observed vessels. Previously,
we have shown using microspheres that cerebral blood flow is
virtually zero in all brain areas examined during the ischemic
period.19 Venous blood was withdrawn as necessary to maintain
mean arterial blood pressure near normal values. At the end of the
ischemic period, the infusion tube was clamped, and the intracranial
pressure returned to preischemic values. The heparinized blood was
reinfused intravenously.
Experimental Design
After obtaining stable baseline arteriolar diameters, we examined the
responses of cerebral arterioles to NMDA (10, 50, 100 mmol/L,
except in group 7). NMDA and all other drugs were dissolved in
aCSF and administered topically through the injectable ports of the
cranial window onto the brain surface with single application.
Arteriolar diameters were measured continuously for 5 to 7 minutes
for each dose of NMDA. Then the window was flushed with aCSF,
and the arteriolar diameters returned to baseline values. Instrumented
piglets (n549) were then divided into 7 groups, as follows.
Group 1 (n54)
To assess whether diazoxide may have direct effect on NMDA-
induced vasodilation, in the first group the animals were treated with
10 mmol/L diazoxide for 10 minutes but did not undergo ischemia.
NMDA challenge was repeated 1 hour after treatment with
diazoxide.
Group 2 (n58)
To repeat our previous findings on attenuation of NMDA-induced
vasodilation by I/R, in this group the piglets received vehicle (aCSF)
and were exposed to 10 minutes of global cerebral ischemia followed
by reperfusion. In all ischemia groups, NMDA-induced changes in
pial arteriolar diameters were reexamined after the first hour of
reperfusion. We have shown that attenuation of cerebral vasodilation
to NMDA is greatest 1 hour after I/R (1 hour is also the shortest time
after I/R at which the measurements are technically feasible).
Groups 3 to 5 (n58, n58, and n512, Respectively)
To investigate the effect of diazoxide on preservation of NMDA-
induced vasodilation, in these groups the piglets were pretreated with
1, 5, and 10 mmol/L diazoxide, respectively, for 10 minutes before
the initiation of 10 minutes of global cerebral ischemia. The
diazoxide was removed by flushing the window with aCSF just
before the initiation of ischemia.
Group 6 (n55)
To investigate the inhibitory effect of 5-HD on KATP channels
activated by diazoxide, the piglets were pretreated with 100 mmol/L
5-HD for 5 minutes, followed by coapplication of 100 mmol/L 5-HD
and 10 mmol/L diazoxide for 10 minutes before 10 minutes of
ischemia. The diazoxide and 5-HD were removed by flushing the
window with aCSF just before the initiation of ischemia.
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Group 7 (n54)
To study the effect of 5-HD on the sarcolemmal KATP channels and
the vascular response to NMDA, we examined the cerebral arteriolar
responses to the nonselective KATP channel opener aprikalim
(10 mmol/L) followed by 100 mmol/L NMDA. Then we coapplied
10 mmol/L aprikalim and 100 mmol/L 5-HD for 10 minutes. We
repeated the NMDA challenge 1 hour after pretreatment with
5-HD1aprikalim. Previously we have shown that aprikalim treat-
ment does not affect the vascular response to NMDA.6 Between each
drug application we flushed the window several times with aCSF,
until arteriolar diameters returned to baseline values.
Drugs
The drugs used in this study were NMDA (Sigma), diazoxide
(Sigma), 5-HD (H135, Research Biochemicals International), and
aprikalim (Rhone-Roulenc-Rohrer).
Statistical Analysis
Data are expressed as mean6SEM. Pial arteriolar diameter data were
analyzed with repeated-measures ANOVA, followed by pairwise
comparisons using the Student-Newman-Keuls test when appropri-
ate. Percent preservations of preischemic vasodilation data were
analyzed with 1-tailed t test. P values of ,0.05 were considered
statistically significant.
Results
Arterial blood pressure was in the normal range and was not
significantly different before and 1 hour after ischemia; for
instance, in group 5 arterial pressure was 7064 mm Hg
before and 6864 mm Hg after I/R (n512).
Topical application of diazoxide did not affect pial vascu-
lar diameters significantly. Typically, there was only a
transient dilation immediately on application of diazoxide.
Percent changes from baseline diameters were as follows:
group 3, no vasoactivity was observed; group 4, 261%; and
group 5, 963%. Vascular diameters quickly returned to
baseline values in 2 to 3 minutes, and none of these changes
were significantly different from baseline values.
NMDA elicited dose-dependent pial arteriolar vasodilation
(Figures 1 and 2). In group 1, 10 mmol/L diazoxide did not
potentiate or attenuate vascular dilations to NMDA 1 hour
after diazoxide treatment (Figure 1). Baseline arteriolar di-
ameters were 10062 mm before and 10066 mm 1 hour after
diazoxide treatment. Percent changes in pial arteriolar diam-
eter from baseline to 10, 50, and 100 mmol/L NMDA (before
versus 1 hour after diazoxide treatment) were 361% versus
461%, 2867% versus 2669%, and 5068% versus 4768%,
respectively.
Global cerebral ischemia (10 minutes) followed by reper-
fusion significantly reduced pial arteriolar responses to
NMDA (Figure 2). In group 2, baseline arteriolar diameters
were 10063 mm before and 10364 mm 1 hour after ische-
mia. Percent changes in pial arteriolar diameter from baseline
to 10, 50, and 100 mmol/L NMDA (before versus 1 hour after
ischemia) were 662% versus 261%, 2865% versus 963%,
and 3865% versus 1664%, respectively. Thus, vascular
dilations to 100 mmol/L NMDA were diminished by '50%
(Figure 3).
Diazoxide exhibited a dose-dependent effect on preserva-
tion of NMDA-induced vasodilation after I/R. In group 3,
decreases in pial arterial responsiveness to NMDA were
similar to those observed in group 2 (Figures 2 and 3). In
group 3, baseline arteriolar diameters were 10263 mm before
and 10463 mm 1 hour after ischemia. Percent changes in pial
arteriolar diameter from baseline to 10, 50, and 100 mmol/L
NMDA (before versus 1 hour after ischemia) were 562%
versus 361%, 2067% versus 862%, and 3865% versus
1963%, respectively. In contrast, in groups 4 and 5 we found
a dose-dependent preservation of pial vascular responses to
NMDA (Figures 2 and 3). More specifically, in group 4,
baseline arteriolar diameters were 9563 mm before and
9564 mm 1 hour after ischemia. Percent changes in pial
arteriolar diameter from baseline to 10, 50, and 100 mmol/L
NMDA (before versus 1 hour after ischemia) were 460%
versus 762%, 30610% versus 2366%, and 4566% versus
3763%, respectively. In group 5, baseline arteriolar diame-
ters were 10266 mm before and 10665 mm 1 hour after
ischemia. Percent changes in pial arteriolar diameter from
baseline to 10, 50, and 100 mmol/L NMDA (before versus 1
hour after ischemia) were 761% versus 662%, 2865%
versus 2464%, and 3665% versus 3264%, respectively.
Therefore, pretreatment with 10 mmol/L diazoxide resulted in
virtually full preservation of pial arteriolar responses to
NMDA 1 hour after I/R compared with preischemic values.
Topical application of the KATP channel antagonist 5-HD
and coapplication of 5-HD with diazoxide did not alter pial
arteriolar diameters. In addition, 5-HD treatment did not
affect pial arteriolar responses to NMDA. In group 7, baseline
arteriolar diameters were 10569 mm before and 10367 mm
1 hour after pretreatment with 5-HD. Percent changes in pial
arteriolar diameter from baseline to 100 mmol/L NMDA
(before versus 1 hour after 5-HD treatment) were 5263%
versus 5667%. However, pretreatment with 5-HD and dia-
zoxide abolished the protection on NMDA-induced vasodi-
lation achieved by diazoxide alone (Figures 2 and 3). In group
6, baseline arteriolar diameters were 9066 mm before and
9266 mm 1 hour after ischemia. Percent changes in pial
arteriolar diameter from baseline to 10, 50, and 100 mmol/L
NMDA (before versus 1 hour after ischemia) were 361%
versus 060%, 40612% versus 1966%, and 6167% versus
3365%, respectively. Interestingly, coapplication of 5-HD
with aprikalim did not block the vasodilation elicited by
aprikalim. In group 7, pial baseline arteriolar diameters were
Figure 1. Effect of 10 mmol/L diazoxide on pial arteriolar
responses to NMDA. NMDA induced dose-dependent vasodila-
tion that was unaffected 1 hour after topical application of dia-
zoxide for 10 minutes (n54). *P,0.05, significantly different from
corresponding baseline diameter (base).
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10268 mm before application of aprikalim alone and
10167 mm before coapplication of aprikalim and 5-HD.
Percent changes in pial arteriolar diameter from baseline to
10 mmol/L aprikalim were 6566% versus 6566% (aprikalim
alone versus aprikalim15-HD, respectively).
Discussion
The major finding of the present study is that the selective
mitoKATP channel opener diazoxide dose-dependently pre-
serves NMDA-induced cerebral arteriolar vasodilation after
I/R in piglets. Since NMDA-induced vasodilation is depen-
dent on intact neuronal function, we present evidence for the
first time showing an in vivo protective effect of diazoxide
after I/R in the central nervous system.
Previously, we found that the nonselective KATP channel
opener aprikalim protected NMDA-induced vasodilation af-
ter combined hypoxia-ischemia.6 The protective effect of
aprikalim was shown to be mediated by neuronal rather than
vascular KATP channels and was independent of the vasodila-
tion elicited by aprikalim. Our present data confirm that the
protective effect of pretreatment with K1 channel openers is
independent of vasodilation accompanied by the administra-
tion of such drugs: diazoxide showed no significant vasoac-
tivity but preserved NMDA-induced dilation. The beneficial
effects of KATP channel openers reducing injury by I/R have
been most extensively studied in the heart. KATP channels
serve as the final common pathway in the event of IPC, a
phenomenon in which short periods of ischemia protect the
heart from subsequent exposure of a more prolonged period
of ischemia. K1 channel openers mimic IPC,15–18 and the
protection by IPC is blocked by KATP channel inhibitors.20–22
The exact mechanism of this remarkable effect has not been
elucidated.
The discovery of mitoKATP channels added further com-
plexity to the interpretation of experimental data from phar-
macological interventions on these channels. Unfortunately,
there are no absolutely selective pharmacological tools to
assess the mitoKATP channels in vivo. However, a consistent
and unique feature of these channels is their remarkably
selective sensitivity to opening by diazoxide. The mitoKATP
channel was found to be .2000-fold more sensitive to
diazoxide than the sarcolemmal KATP channel in bovine
cardiac myocytes (K1/2 was 0.4 mmol/L for mitoKATP channel
versus 855 mmol/L for sarcolemmal KATP channel). In con-
trast, cromakalim was an equally potent opener of both
mitochondrial and plasma membranes.10 Subsequently, mi-
toKATP channel selective concentrations (5 to 20 mmol/L) of
diazoxide have been demonstrated to improve functional
recovery in isolated rat hearts after I/R in a manner similar to
that of a nonselective KATP channel opener, cromakalim. The
cardioprotection by diazoxide was inhibited by KATP channel
inhibitors glibenclamide and 5-HD, confirming the effect of
diazoxide via KATP channels.17 In a different study, in intact
Figure 2. Changes in pial arteriolar diameters in response to
NMDA 1 hour after 10 minutes of cerebral ischemia. Baseline
diameters (base) did not change significantly in any groups after
I/R. However, in the nontreated animals arteriolar responses to
50 and 100 mmol/L NMDA were severely reduced by '50%.
Pretreatment with 1 mmol/L diazoxide (diaz) did not affect the
reduction in NMDA-induced vascular dilation by I/R. In contrast,
pretreatment with 5 or 10 mmol/L diazoxide resulted in pre-
served vascular responses; the changes in pial arteriolar diame-
ters were not significantly different compared with preischemic
values. Coapplication of 100 mmol/L 5-HD, a relatively specific
inhibitor of mitoKATP channels with 10 mmol/L diazoxide attenu-
ated the protective effect of diazoxide. *P,0.05, significantly
different from corresponding preischemic value.
Figure 3. Protective effect of diazoxide (diaz) on 100 mmol/L
NMDA–induced pial arteriolar dilation. Data are expressed as
percent preservation of dilation compared with preischemic val-
ues. Note the dose-dependent preservation of vascular
responses in the diazoxide-treated groups; at 10 mmol/L diazox-
ide the vascular response was virtually identical to preischemic
value. 5-HD antagonized the effect of diazoxide. *Significantly
different from preischemic value.
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rabbit ventricular myocytes, diazoxide induced mitochondrial
depolarization, demonstrated by flavoprotein fluorescence
with a K1/2 of 27 mmol/L, but did not affect the simulta-
neously measured sarcolemmal KATP channel current.16 These
findings and others in the literature (for recent review, see
Reference 15) strongly indicate the involvement of mitoKATP
channels in the development of acute and perhaps delayed
IPC in the heart.
In our present experiments we used topical diazoxide (1 to
10 mmol/L) in the mitoKATP channel–selective dose range.
We did not test directly whether only mitoKATP channels were
activated by diazoxide, but fortunately a good indication of
selective activation was the absence of significant vasodila-
tion accompanied by application of diazoxide. The vasodila-
tory effect of K1 channel openers on cerebral arterioles was
directly mediated by the sarcolemmal K1 channels. Admin-
istration of 5 to 10 mmol/L diazoxide elicited only 2% to 9%
arteriolar dilation, and the response was transient, ie, it did
not last for .1 to 2 minutes. In contrast, we found that the
nonselective KATP channel opener aprikalim (10 mmol/L)
elicits '60% to 70% increases in vascular diameters, and the
vasodilation does not wane. Moreover, the dose-dependent
effect of diazoxide on preservation of the NMDA-induced
vasodilation after I/R was inhibited by the selective KATP
channel antagonist 5-HD, and 5-HD was found to be selective
for mitoKATP channels, at least in some experimental de-
signs.16,17,23 Additionally, in our experimental model 5-HD
did not inhibit the vasodilation induced by aprikalim, sug-
gesting minor effects on plasmolemmal KATP channel chan-
nels. These observations, together with those of the literature,
lead us to conclude that the protective effect of diazoxide on
neuronal-vascular function after I/R is probably mediated by
activation of mitoKATP channels.
The mechanism by which activation of mitoKATP channels
may lead to increased resistance to I/R remains to be clarified.
In our experimental model, NMDA-induced vascular re-
sponse is severely attenuated at 1 hour after I/R, and respon-
siveness gradually returns over the time course of 2 to 4
hours.5,24 The duration of global cerebral ischemia (10 min-
utes) used in the present study has been thought to cause only
reversible mitochondrial alterations, ie, mitochondria have
been shown to recover full function 1 to 2 hours after
reperfusion.25,26 Thus, the attenuation of the NMDA-
mediated cerebral arteriolar response is not likely due to
energy failure by inhibited mitochondrial function. This
statement is further supported by our previous findings that
kainate-induced vasodilation is resistant to ischemia in the
same experimental model.27 Additionally, neuronal NO syn-
thase levels and activity are unchanged by I/R, and cerebral
arterioles show normal responses to exogenous NO donors
such as sodium nitroprusside after ischemia.5,6 Therefore, the
primary target of I/R may be the NMDA receptor itself. The
acute effect of ischemia on NMDA-induced pial arteriolar
vasodilation has been amply demonstrated to be mediated by
ROS (Figure 4). Thus, NMDA-induced vascular response has
been found to be preserved by ROS scavengers and inhibitors
of cyclooxygenase (COX) activity,4,5,8,24 a major source of
ROS after I/R.28 Our recent observations on the preservation
of neural function with K1 channel openers after hypoxia-is-
chemia were somewhat at odds with the general scheme of
the pathological mechanism of the effect of I/R on NMDA-
induced neuronal-vascular sequence. However, our present
results may link the beneficial effect of K1 channel openers
on preservation of NMDA-induced vasodilation to reducing
oxidative stress on the neurons involved in this response. We
speculate that activation of mitoKATP channels by K1 channel
openers may reduce mitochondrial ROS production.
Currently, the physiological role of mitoKATP channels is
still debated and mostly speculative. Briefly, mitoKATP chan-
nels seem to control the activity of the electron transport
chain via regulating mitochondrial matrix volume by regu-
lated K1 uptake. The physiological patterns of activation and
inhibition of these channels are largely unknown, but ironi-
cally the physiological role of ATP as a regulator is unlike-
ly.29 In isolated mitochondria, K1 channel openers induce
slight swelling, partially dissipate the transmembrane poten-
tial (DC, negative inside), but increase the activity of electron
transport chain and hence the chemical proton gradient (DpH,
alkaline inside); thus, the total protonmotive hardly chang-
es.10–14 However, the activity of numerous important trans-
port mechanisms depends on either DC or DpH. One such
possibly crucial “metabolite” may be Ca21. Mitochondria
readily uptake Ca21 when intracellular levels increase above
a so-called mitochondrial buffer concentration. Ca21 is trans-
ported through the mitochondrial inner membrane via the
electrogenic Ca21 uniporter down its electrochemical gradi-
ent, and thus the rate of this transport is dependent on DC.30
Mitochondrial Ca21 overload substantially influences the
recovery of mitochondrial function after ischemic stress: for
example, increased mitochondrial Ca21 sequestration has
Figure 4. Preservation of NMDA-induced cerebral vasodilation
after I/R. The most sensitive component of this neuronal-
vascular sequence to I/R may be the NMDA receptor itself. ROS
produced by mitochondria and COX seem to play a pivotal role
in attenuating the NMDA-induced vasodilation. Thus, pretreat-
ment with ROS scavengers, the COX inhibitor indomethacin, or
the protein (including COX) synthesis inhibitor cycloheximide
shortly before I/R results in preserved vascular responsiveness
to NMDA. NMDA-induced dilation is also preserved by pretreat-
ment with diazoxide, a selective mitoKATP channel opener, and
other K1 channel openers (KCO-s). Activation of mitoKATP chan-
nels may reduce generation of ROS in reperfusion. Reduction in
either COX-derived or mitochondrial ROS production may be
sufficient to preserve the vascular response to NMDA after I/R.
However, a potentiating interaction between these sources of
ROS is conceivable but unknown.
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been demonstrated to increase production of ROS.31,32 Open-
ing of mitoKATP channels should decrease mitochondrial Ca21
uptake by decreasing DC, and in fact K1 channel openers
induce release of Ca21 from Ca21-preloaded mitochondria in
vitro.11
In summary, we conclude that diazoxide in a mitoKATP
channel–selective range dose-dependently preserves neuronal
function demonstrated by NMDA-induced arteriolar dilation
after I/R. This acute effect of mitoKATP channel openers may
be mediated by decreasing mitochondrial ROS production in
the immediate reperfusion. This effect may be important in
the protective effect of other nonspecific K1 channel openers
as well. Our findings may offer the development of new
therapies to reduce neuronal injury after global hypoxic-is-
chemic stress in the newborn.
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Editorial Comment
The protection of tissues and organs, after I/R and other
pathological conditions, is an extremely important but often
disappointing area of investigation. Such protection is of
particular importance in heart and brain, vital organs that are
most vulnerable to I/R. Interestingly, a brief activation of
KATP before an ischemic event has been reported to provide a
reasonable degree of tissue protection.1 Although the mech-
anism behind this protective effect of KATP stimulation was
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not known, a reasonable hypothesis stated that protection
occurred through hyperpolarizing the plasma membrane.
Hyperpolarization would reduce the probability and/or the
duration of an action potential. Protection would be afforded
in 2 ways. First, the energy requirement would be reduced at
a time when energy supply in the form of ATP is likely to be
compromised. Second, a decrease in the number and/or
duration of action potentials would reduce influx of Ca12 into
the cell and help to prevent intracellular Ca12 concentrations
from reaching toxic levels.
However, several studies in heart demonstrated that the
abbreviation of action potentials could be dissociated from
protection conferred by KATP channel openers.2–6 With this
knowledge in mind and the discovery of mitochondrial KATP
channels, attention was turned away from the sarcolemma to
KATP channels in the mitochondria. Indeed, a number of
studies in heart strongly support the hypothesis that KATP
openers confer protection through KATP channels located not
on the sarcolemma membrane but on the inner mitochondrial
membrane.2,4
Would the same hold true for cerebral protection after I/R?
Could this be demonstrated in vivo? Domoki and colleagues
asked these questions in the study in the accompanying
article. Convincingly, these authors showed that prior stimu-
lation of mitochondrial KATP channels, not plasma membrane
KATP channels, are involved with cerebral protection (as
measured by preservation of dilator responses to NMDA)
after I/R in the newborn pig. In their studies the authors
reported that the selective mitochondrial KATP opener diazox-
ide restored dilator responses to NMDA that had been
diminished by I/R. Furthermore, the selective mitochondrial
KATP blocker 5-HD antagonized the protective effects of
diazoxide. Although selectivity of these 2 agents had been
demonstrated in heart,1 there was no guarantee that this
selectivity automatically transferred to brain. In a series of
cleverly designed studies, Domoki et al demonstrated that
diazoxide produced only minor and transient dilations (5%
dilation that lasted 2 to 3 minutes) of the pial arteries, whereas
stimulation of KATP channels in the plasma membrane (by
aprikalim) produced large (65% dilation) and sustained dila-
tions. Hence, diazoxide had practically no effect on dilation
and thus plasma membrane KATP channels. Second, 5-HD had
no effect on dilations elicited by opening KATP channels in the
plasma membrane with aprikalim. If 5-HD was not blocking
KATP channels in the plasma membrane, then it was reason-
able to conclude that it was selectively blocking KATP chan-
nels in the mitochondria.
This study by Domoki and colleagues has 2 important
implications. First, it demonstrates the importance of mito-
chondria in the developing pathophysiology after I/R. Sec-
ond, this study provides a potentially important therapy for
treatment of stroke in humans. Cerebral protection by openers
of mitochondrial KATP channels and the study of mitochondria
in the pathophysiology of cerebral insults promise to be
important frontiers for future research.
Robert M. Bryan, Jr, PhD, Guest Editor
Department of Anesthesiology
Baylor College of Medicine
Houston, Texas
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